RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) (AAVIATE)

RGX-314 is being developed as a potential novel one-time gene therapy treatment for the treatment of neovascular (wet) age related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-VEGF therapies have significantly changed the landscape for treatment of wet AMD, becoming the standard of care due to their ability to prevent progression of vision loss in the majority of patients. These therapies, however, require life-long intraocular injections, typically repeated every four to twelve weeks in frequency, to maintain efficacy. Due to the burden of treatment, patients often experience a decline in vision with reduced frequency of treatment over time.

This phase 2, randomized, dose-escalation study is designed to evaluate the efficacy, safety and tolerability of RGX-314 gene therapy in subjects with nAMD. Approximately 115 participants who meet the inclusion/exclusion criteria will be enrolled into one of 6 cohorts. Participants will be randomized in Cohorts 1 and 2 to receive RGX-314 or ranibizumab control, and participants enrolled in Cohorts 3 through 5 will receive RGX-314. Participants enrolled in Cohort 6 will receive RGX-314 and will be randomized to one of two different post-procedural steroid regimens. Cohort 1 will evaluate RGX-314 Dose 1, Cohorts 2 and 3 will evaluate RGX-314 Dose 2, and Cohorts 4, 5, and 6 will evaluate RGX-314 Dose 3. Participants will be evaluated for efficacy, safety and tolerability of RGX-314 throughout the study.

Eligibility Criteria:
Inclusion Criteria:

* Age \>/= 50 and \</= 89
* Diagnosis of CNV secondary to age-related macular degeneration in the study eye.
* Participants must have demonstrated a meaningful response to anti-VEGF therapy.
* Willing and able to provide written, signed informed consent for this study.

Exclusion Criteria:

* CNV or macular edema in the study eye secondary to any causes other than AMD.
* Subfoveal fibrosis or atrophy in study eye.
* Participants who have had a prior vitrectomy.
* Active or history of retinal detachment in the study eye.
* History of intravitreal therapy in the study eye, such as intravitreal steroid injection or investigational product (IP), other than anti-VEGF therapy, in the 6 months prior to study entry.
* Received any gene therapy.
* Any condition preventing visualization of the fundus or VA improvement in the study eye, eg, cataract.
* History of intraocular surgery in the study eye within 12 weeks of study entry.
* Receipt of any IP within 30 days of study entry or 5 half-lives of the IP.
* Myocardial infarction, cerebrovascular accident, or transient ischemic attacks within 6 months of study entry.
* Cohorts 1 - 5 only: Uncontrolled glaucoma in the study eye.

COHORT 6 ONLY:

* Active or history of glaucoma or ocular hypertension in the study eye.

  * Certain OCT characteristics including: Large Pigment Epithelial Detachments (PED), clinically significant Epiretinal Membrane (ERM) in the study eye at Visit 1.

Note: Other inclusion/exclusion criteria apply.